More

    Viatris

    Viatris Inc. history, profile and corporate video

       Viatris Inc. is a global healthcare company headquartered in Pittsburgh, Pennsylvania, United States.

    HISTORY


       Viatris was formed in 2020 through the merger of Mylan and Upjohn, a legacy division of Pfizer.

       The name Viatris is rooted in Latin and comes from the vision of providing a path (“VIA”) to three (“TRIS”) main goals of the company: expanding access to medicines, leading by innovating to meet patient needs, and being a trusted partner for the healthcare community worldwide.

    MYLAN

       Mylan was founded in 1961 in White Sulphur Springs, West Virginia, United States, to ensure access to affordable medicine in difficult-to-reach communities. The company was named after one of the company’s co-founders, Milan “Mike” Puskar.

       In the early years, the company bought finished-dose medicines and resold them from the trunk of a Pontiac Bonneville to rural pharmacies and physicians throughout the Appalachian region of the U.S.

       In 1966, Mylan received approval to manufacture the antibiotic penicillin G, marking the company’s entrance into generic pharmaceuticals.

       In 1984, the company introduced an antihypertensive called Maxzide®, making Mylan the first generics manufacturer in the world to patent a new drug.

       In 1995, after acquiring a number of companies, Mylan had one of the most dispensed lines of pharmaceuticals in America, brand or generic.

       In January 2007, the company acquired a majority stake in Matrix Laboratories, an Indian supplier of active pharmaceutical ingredients.

       In October 2007, the company acquired the generics division of Merck KGaA.

    - Advertisement -

       In 2013, the company acquired an Indian generic injectable drugs company, Agila Specialties Private.

       In 2015, Mylan acquired the generic drugs business in developed markets of Abbott Laboratories.

       In February 2016, the company announced it would acquire Meda AB.

       In May 2016, the company announced it would acquire Renaissance Acquisition Holdings dermatology division.

    UPJOHN

       Upjohn was born out of Pfizer’s Established Medicines division. It was created in 2018 as a standalone business within Pfizer, focusing on providing medicines for non-communicable diseases (NCDs).

       Upjohn’s portfolio included complex generics and biosimilars, as well as some of the world’s most recognized brands, including CELEBREX® (celecoxib capsules), DILANTIN® (extended phenytoin sodium capsules, USP), LIPITOR® (atorvastatin calcium), LYRICA® (pregabalin) and VIAGRA® (sildenafil citrate) – category-leading products across cardiovascular, pain, mental health and urology therapeutic areas.

    PRODUCTS


       Viatris’ global portfolio delivers global iconic and key brands, biosimilars, generics – including complex and branded generics – and over-the-counter products.

       Viatris operates over 40 manufacturing sites, producing oral solid doses, injectables, complex dosage forms, and active pharmaceutical ingredients.

    THERAPEUTIC AREAS


       Viatris medicines cover various therapeutic areas spanning both non-communicable and infectious diseases. It also offers support services such as diagnostic clinics, educational seminars, and digital tools.

    • Cardiovascular;
    • Infectious disease;
    • Oncology;
    • Immunology;
    • CNS and anesthesia;
    • Women’s Healthcare;
    • Diabetes and metabolism;
    • Gastroenterology;
    • Respiratory and allergy;
    • Dermatology.

       The company is also one of the leading companies in treating infectious diseases such as HIV/AIDS, hepatitis and tuberculosis.

    VIATRIS BRANDS


    • Lipitor
    • Norvasc
    • Caduet
    • Inspra
    • Nitrostat
    • Revatio
    • Dilantin
    • Lyrica
    • Neurontin
    • Relpax
    • Sermino
    • Celebrex
    • Zoloft
    • Effexor XR
    • Xanax
    • Geodon
    • Viagra
    • Detrol LA
    • Cardura
    • Xalatan
    • Creon-12000u-5
    • Creon-25000-Capsules-4
    • Dymista
    • Influvac
    • Perforomist
    • Yupelri

       With a global workforce of over 38,000 employees and a presence in more than 165 countries and territories across North America, Europe and the Asia Pacific region, Viatris has one of the largest global commercial infrastructures in the industry. According to Forbes, it is considered one of the Largest Public Companies in the World.

    *Information from Forbes.com, Wikipedia.org, and www.viatris.com/en.

    **Video published on YouTube by “Companies History“.

    Advertisment

    Advertisment

    Related videos

    Advertisment

    Advertisment